Beyond FSP1 there are therapeutic opportunities across the CoQ 10 oxidoreductase network While FSP1 currently has the strongest targetability signal, other CoQ 10 oxidoreductases may be therapeutically leveraged in defined genetic, metabolic or tissue contexts: (1) DHODH axis (mitochondrial defense in select contexts): DHODH connects pyrimidine synthesis to mitochondrial CoQ reduction, and in some settings, DHODH inhibition has been proposed to heighten ferroptosis sensitivity, especially in GPX4-low states
Although the company discourages using the vial for multi-dosing (it doesnt contain a preservative), one option would be to inject 1 mg (0.05 mL) weekly for 2 weeks, 2 mg (0.1 mL) weekly for 2 weeks, then 4 mg (0.2 ml) weekly
Beneficial for cardiovascular health, autism, depression, neurological symptoms (restless legs, migraines), and prevention of certain birth defects
Avoid standard oral B12 supplements under 1000 micrograms they fail to correct deficiency in most cases
Feelders RA, de Bruin C, Pereira AM, Romijn JA, Netea-Maier RT, Hermus AR, Zelissen PM, van Heerebeek R, de Jong FH, van der Lely AJ, de Herder WW, Hofland LJ, Lamberts SW